Parkinson’s UK has awarded £55,000 to Cellestial Health for an industrial-academic collaboration with The University of Manchester.

The research will continue exploring how astrocytes might hold the key to new treatments for Parkinson’s. This builds on promising findings from earlier work showing that restoring astrocyte networks could protect brain function.

Led by Dr Nataly Hastings, this project brings together Cellestial Health – a University of Cambridge spin-out – with experts at The University of Manchester, including Dr Roy Ng, our Centre’s preclinical lead for dementia, and Professor Richard Unwin. By combining strengths in astrocyte biology, proteomics and neuroinflammation, the team will study brain tissue and CSF samples from people with Parkinson’s to better understand when and how astrocyte-targeted therapies could benefit those living with Parkinson’s.

This collaboration is a brilliant example of academic-industry partnership, with real potential to unlock new therapeutic targets and improve lives.

🔗 Learn more: Further funding for pioneering approach to slow or stop Parkinson’s | Parkinson’s UK

Related